Symbiotec Pharmalab Ltd IPO
Status: Closed
Overview
IPO date
24 Aug 2026 to 27 Aug 2026
Face value
₹ 2 per share
Price
₹ 938 to ₹988 per share
Issue Size
17,786,442 shares
(aggregating up to ₹ 1757 Cr)
(aggregating up to ₹ 1757 Cr)
Allotment Date
28 Aug 2026
Listing at
NSE
Issue type
Book Building
Sector
Pharmaceuticals
Unlock Stock of the Month
T&C*
Strengths vs Risks of Symbiotec Pharmalab Ltd
Know the pros & cons
Strengths
- Global leadership in corticosteroid and steroidal hormone APIs.
- Long-standing relationships with domestic and global customer base.
- Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record.
- Continuous investment in R&D, with leading technological capabilities among Indian peers.
- Ability to leverage science and existing competencies to increase total addressable market and deepen intellectual property-driven offerings.
Risks
- The company derives almost all of its revenue from the sale of APIs, which collectively constituted 96.07%, 99.10% and 100.00% of the company's revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Further, its top five APIs constituted 62.27%, 63.16% and 60.37% of the company's revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Any reduction in demand for APIs, and its top products in particular, or disruption in production, could have an adverse effect on the company's business, results of operations, financial condition and cash flows.
- The company's manufacturing facilities is subject to periodic inspections and audits by regulatory authorities and its customers. Any manufacturing or quality control failures may subject it to regulatory action, damage the company's reputation and have an adverse effect on its business, results of operations, financial condition and cash flows.
- The company exports its products to various countries and the company's revenue from external customers outside India as per Ind AS 108 - "Operating Segments" represented 67.04%, 55.19% and 59.97% of its revenue from operations in Fiscals 2026, 2025 and 2024, respectively. The company's inability to handle risks associated with its export sales could adversely affect the company's sales to customers in foreign countries, its results of operations, financial condition and cash flows.
- In Fiscals 2026, 2025 and 2024, revenue from the United States represented 13.12%, 4.02% and 8.97% of the company's revenue from operations. The imposition of tariffs or other anti-outsourcing legislation by the United States could adversely affect its results of operations, financial condition and cash flows.
- The company derives a substantial portion of its revenue from certain key customers. Revenue generated from the company's top ten customers accounted for 57.59%, 55.90% and 61.65% of its revenue from sale of product in Fiscals 2026, 2025 and 2024, respectively. Loss of the company's relationship with any of these customers or delays or reductions in their orders could have an adverse effect on its business, results of operations, financial condition and cash flows.
- The company's manufacturing facilities and dedicated R&D centres are located in the state of Madhya Pradesh in India. Any adverse developments affecting Madhya Pradesh or its surrounding regions could adversely affect its business, results of operations, financial condition and cash flows. A slowdown, interruption or shutdown in the company's manufacturing operations could have an adverse effect on its business, results of operations, financial condition and cash flows.
- The company depends on certain suppliers for raw materials for its operations. Purchases from the company's top ten suppliers accounted for 25.50%, 18.41% and 50.33% of its total expenses in Fiscals 2026, 2025 and 2024, respectively. Any loss of such suppliers or non-performance of their obligations could adversely affect the company's business, results of operations, financial condition and cash flows.
- The company operates in a highly competitive market. Its faces competition both within the company's API manufacturing business and in its role as a CDMO, which the company has recently commenced. An inability to compete effectively may adversely affect its business, results of operations, financial condition and cash flows.
- The company procures a portion of its raw material requirements from different countries, including China and the United States. Any adverse developments in these countries, or the laws governing the company's imports from these countries, could disrupt its raw material supply and adversely affect the company's results of operations, financial condition and cash flows.
- The company's success depends on its ability to develop and commercialise new products in a timely manner. If the company's research and development efforts does not succeed, or the products its commercialise does not perform as expected, the introduction of new products may be hindered, which could adversely affect the company's business, results of operations, financial condition and cash flows.
- The company's operations involve activities and materials which is hazardous in nature and could result in a suspension of operations, injury to its personnel, emission of pollutants or the imposition of civil or criminal liabilities, which could adversely affect the company's business, results of operations, financial condition and cash flows.
- The company is subject to extensive regulation from governmental and international authorities and if the company fails to obtain, maintain or renew the statutory and regulatory licenses, permits and approvals required for its business, the company's results of operations, financial condition and cash flows may be adversely affected. Further, non-compliance with, and changes in, environmental, health and safety, and labor laws and other applicable regulations may adversely affect its business, results of operations, financial condition and cash flows.
- The company has issued Equity Shares during the preceding 12 months at prices that may be lower than the Offer Price.
- The company's business agreements include certain restrictive covenants which may restrict its business operations.
- If the company's products or other products containing its corticosteroid or steroidal-hormone APIs cause, or are perceived to cause, severe side effects, the sales of such products may decrease, which may have an adverse effect on the company's results of operations, financial condition and cash flows.
- The company's operations are labour intensive, and its may be subject to strikes, work stoppages or increased wages demands by the company's employees, which could adversely affect its business, results of operations, financial condition and cash flows.
- The company requires working capital for its continued operation and growth. The company's inability to meet its working capital requirements could have an adverse effect on the company's business, results of operations, financial condition and cash flows.
- The company's statutory auditors examination report on the Restated Consolidated Summary Statements discloses certain modifications included in their report on the consolidated financial statements as at and for the years ended March 31, 2026, March 31, 2025 and March 31, 2024.
- The company has in the past been in non-compliance with Section 383A of the Companies Act, 1956 and have filed a compounding application with the National Company Law Tribunal, Indore ("NCLT, Indore"). Its cannot assure you that there will be no such non-compliances in the future and that the company will not be subject to any action including payment of penalty amount.
- Motilal Oswal Investment Advisors Limited, one of the Book Running Lead Managers, is an associate of one of the company's Investor Selling Shareholders, namely, India Business Excellence Fund - III.
- The company's past performance may not be indicative of its future growth. The company may not be able to effectively sustain its growth or execute the company's growth strategies, which could have an adverse effect on its business, results of operations, financial condition and cash flows.
- The company may not be successful in commercialising its complex injectables offerings, which the company intends to focus on through the commissioned Mhow Facility, which may adversely affect the company's results of operations, financial condition and cash flows.
- Certain of the company's raw materials and production processes are sensitive and must be collected, stored and transported in specific conditions. Failures to handle these materials and products appropriately, or undertake the sensitive processes with their complex steps, may lead to loss of the raw materials, inability to sell the products and adversely affect the company's business, results of operations, financial condition and cash flows.
- Some of the company's Promoters and Directors may have interest in entities in businesses similar to its, which may result in conflicts of interest with it.
- The company is in the process of expanding its biologics capacity by setting up the Biologics Facility in Ujjain. The establishment of this facility may be subject to delays, cost overruns, or other risks and uncertainties.
- The company's CDMO business, which commenced in 2025 and which the company is expanding, is subject to risks including seasonality, which may result in seasonal fluctuations in operating results and cash flows, non-compliance with the terms of its contracts with customers, and expiry of patent protection of customers and limited number of customers. Any failures to grow the company's CDMO business or mitigate these risks could adversely affect its results of operations, financial condition and cash flows.
- The company's benefit from incentives and schemes of the Government of India. Cancellation of such incentives and schemes, or its inability to meet their conditions, may adversely affect the company's results of operations, financial condition and cash flows.
- Introduction of stricter norms regulating pharmaceutical marketing practices could affect the company's ability to effectively market its products, which may have an adverse effect on the company's business, results of operations and financial condition.
- The company has entered into certain transactions with related parties in the past and may continue to do so in the future. These transactions or any future transactions with its related parties could potentially involve conflicts of interest.
- The company's operations are dependent on an adequate and uninterrupted external supply of electricity, fuel, and water. Any disruption or shortage in electricity, fuel or water may lead to disruption in operations, higher operating cost and consequent decline in the company's operating margins.
- The Investor Selling Shareholders, India Business Excellence Fund-III, together with its co-investors, and Rosewood Investments, have transferred Equity Shares held by them, to one of the company's Promoters, Satwani Holdings LLP, pursuant to the upside sharing arrangement as provided for in the Investment Agreement which has resulted in an increase in the pre-Offer shareholding of its Promoter, Satwani Holdings LLP.
- There are certain restrictions on operations within a special economic zone ("SEZ") in India. The company's claim deductions under special tax holidays for its Pithampur Facility, located in an SEZ in India. Any change in these tax holidays, or failures to comply with restrictions applicable to SEZs, may adversely affect its results of operations, financial condition and cash flows.
- Delay or failures in the performance of the company's contracts may adversely affect its business, results of operations, financial condition and cash flows.
- If the company is unable to protect its proprietary information or other intellectual property, the company's business may be adversely affected.
- Certain of the company's manufacturing facilities are not located on land owned by it and the company has only leasehold rights. In the event its loses or is unable to renew such leasehold rights, the company's business, results of operations, financial condition and cash flows may be adversely affected.
- Certain of the company's corporate records and filings are not traceable or have certain discrepancies. Its cannot assure you that regulatory proceedings or actions will not be initiated against the company in the future and its will not be subject to any penalty imposed by the competent regulatory authority in this regard.
- Under-utilisation of the company's manufacturing capacities over extended periods, or significant underutilisation in the short term could increase its cost of production and the company's operating costs and adversely impact its business, growth prospects and future financial performance.
- The company's Promoters and certain members of the Promoter Group have encumbered certain Equity Shares of the Company held by them in favour of Beacon Trusteeship Limited, (on behalf of debenture holder, Nomura Capital (India) Private Limited, which is an affiliate of one of its BRLMs, Nomura Financial Advisory and Securities (India) Private Limited) by way of pledge. Any enforcement of such pledge by Beacon Trusteeship Limited could dilute the shareholding of the company's Promoters, which may adversely affect its business and financial condition.
- The company held a market share of over 50% by volume in products such as Hydrocortisone, Testosterone and Methylprednisolone, with market shares of 80.1%, 76.4% and 76.0% respectively, in Fiscal 2026. (Source: F&S Report) The loss of market share may adversely affect its business, results of operations, financial condition and cash flows.
- The company has capital expenditure requirements and may requires additional capital and financing in the future. If the company is unable to obtain the required additional capital and financing when needed, its results of operations, financial condition and cash flows may be adversely affected.
- The company proposes to repay or prepay all or a portion of certain outstanding borrowings availed by the Company.
- The company's Promoter and Chairman and Managing Director, Anil Satwani, has provided personal guarantees for certain borrowings availed by one of its Subsidiaries. Any failures by the Company to repay such loans could trigger repayment obligations on the company's Promoter, which may impact their ability to effectively service their obligations and adversely affect its business and operations.
- The company has extended certain loans to its Subsidiaries, and extended guarantees on their behalf. Any default by the Subsidiaries in fulfilling their obligations in connection with such indebtedness may lead to nonrecovery or invocation of the guarantees, which could adversely affect the company's results of operations, financial condition and cash flows.
- The company is exposed to risks in relation to the supply of its products, particularly through third party transportation. A failures to deliver the company's products to its customers in an efficient and reliable manner could have an adverse effect on the company's business, results of operations, financial condition and cash flows.
- The Company and certain of its Directors and Subsidiaries are involved in certain legal proceedings. Any adverse decision in such proceedings may have an adverse effect on the company's business, results of operations, financial condition and cash flows.
- The company's funding requirements and proposed deployment of the Net Proceeds of the Offer have not been appraised by a bank or a financial institution and if there are any delays or unanticipated expenses, its business, cash flows, financial condition and results of operations may be adversely affected.
- The company's continued success is dependent on its Promoters, Directors, Senior Management, Key Managerial Personnel and skilled manpower. The company's inability to attract and retain key personnel or the loss of services of such personnel may have an adverse effect on its business prospects.
- The Company will not receive any proceeds from the Offer for Sale.
- The company may pursue strategic acquisitions for inorganic growth in the future. Its may not be able to integrate any future acquisitions or may be faced with operating difficulties due to such integration, which could adversely affect the company's business, results of operations, financial condition and cash flows.
- Changes in technology may render the company's current technologies obsolete or requires it to make substantial capital investments.
- The company is subject to risks arising from exchange rate fluctuations. Failures to effectively manage such risks could adversely affect its results of operations, financial condition and cash flows.
- The company engage contract labour for carrying out certain functions of its business operations. Any default on payments to them by the agencies could lead to disruption of the company's business operations.
- Information technology system failures or interruptions or breaches of the company's network security, confidentiality of technical knowledge and process know-how may interrupt its operations adversely impact the company's business, results of operations, financial condition, cash flows, reputation and prospects.
- The company may be subject to pricing pressure from its customers, which could have an adverse effect on the company's business, results of operations, financial condition and cash flows.
- Certain sections of this Red Herring Prospectus disclose information from the F&S Report which has been prepared exclusively for the Offer and commissioned and paid for by it exclusively in connection with the Offer and any reliance on such information for making an investment decision in the Offer is subject to inherent risks.
- The company's insurance coverage may not adequately protect it against all losses or the insurance cover may not be available for all the losses as per the insurance policy, which could adversely affect business, results of operations, financial condition and cash flows.
- Certain of the company's Subsidiaries have incurred losses during the last three Fiscals and certain of its Subsidiaries have reported negative net worth in the last three Fiscals. The company cannot assure you that its Subsidiaries will be able to generate profits and not incur losses in the future or not report negative net worth.
- Any inability to recover amounts deployed in the company's Subsidiaries, including overseas Subsidiaries, resulting in write-offs may adversely affect its business, results of operations, financial condition and cash flows.
- Information relating to the maximum manufacturing capacity and capacity utilisation of the company's facilities included in this Red Herring Prospectus are based on various assumptions and estimates. These assumptions and estimates may prove to be inaccurate, and its future production and capacity may vary.
- The company's inability to accurately forecast demand for its products and manage the company's inventory may have an adverse effect on its business, results of operations, financial condition and cash flows.
- Any negative publicity or allegations against it, even if untrue, may adversely affect its reputation and trust in the company's services, which could adversely affect its business, results of operations, financial condition and cash flows.
- The company has incurred indebtedness and an inability to comply with repayment and other covenants in the company's financing agreements could adversely affect its business, results of operations, financial condition and cash flows.
- Failures in internal control systems could cause operational errors which may have an adverse effect on the company's reputation, results of operations, financial condition and cash flows.
- The company is subject to counterparty credit risk and any delay in receiving payments, or non-receipt of payments, from its customers could have an adverse effect on the company's business, results of operations, financial condition and cash flows.
- If the company inadvertently infringe on the intellectual property rights of others, its business, results of operations, financial condition and cash flows may be adversely affected.
- The company's operations are susceptible to the risk of manufacture, distribution, and sale of counterfeit, falsified, or sub-standard drugs, particularly in the generic drug segment. Any failures to prevent or detect counterfeit products associated with its brand may have an adverse impact on the company's business, results of operations, financial condition and cash flows.
- Any downgrade of the company's credit ratings could adversely affect its business.
- The company's Promoters, including its Chairman and Managing Director, and certain members of the company's Key Managerial Personnel and Senior Management, hold Equity Shares in the Company and are therefore interested in the Company's performance in addition to their remuneration and reimbursement of expenses.
- The company's Promoters and members of the Promoter Group will continue to hold a significant equity stake in the Company after the Offer and their interests may differ from those of the other shareholders.
- Certain non-GAAP financial measures relating to the company's operations and financial performance have been included in this Red Herring Prospectus. These non-GAAP financial measures are not measures of operating performance or liquidity defined by Ind AS and may not be comparable.
- Any variation in the utilisation of the Net Proceeds as disclosed in this Red Herring Prospectus shall be subject to certain compliance requirements, including prior approval of the shareholders of the Company.
- The company's ability to pay dividends in the future will depends upon its future earnings, financial condition, cash flows, working capital requirements and capital expenditures and the terms of the company's financing arrangements.
- Theft, internal or external fraud or misconduct by the company's employees could adversely affect its results of operations, financial condition and cash flows.
- The company has adopted the Symbiotec Employee Stock Option Plan 2024 ("ESOP Scheme"). The grant of options under the ESOP Scheme may increase the company's employee expenses and may adversely impact its profitability and cash flows.
- The markets addressed by the company subject to certain threats and challenges, which could adversely affect its business, results of operations, financial condition and cash flows.
- If the company's products are found to be infringing on the intellectual property rights of a third-party, its may be required to cease the sale of such infringing products, causing loss of future sales revenue from such products and may also faces liabilities for infringement of intellectual property rights, which may adversely affect the company's business, results of operations, cash flows and financial condition.
Symbiotec Pharmalab Ltd Peer Comparison
Understand the company’s industry standing
Symbiotec Pharmalab Pvt Ltd
Concord Biotech Limited
Divi's Laboratories Limited
Face Value
2
1
2
Standalone / Consolidated
Consolidated
Consolidated
Consolidated
Total Income Rs. Cr.
869.149
1054.9
10560
EPS-Basis
19.1
24.78
96.75
EPS-Diluted
19
24.78
96.75
NAV Per Share
184.69
---
631
P/E-Basic EPS
---
62.47
90.38
P/E-Diluted EPS
---
---
---
RONW(%)
9.48
14
16.5
Latest NAV Period
---
---
---
Latest NAV
---
---
---
How to check the allotment status of Symbiotec Pharmalab Ltd IPO?
Follow the steps
Open link to the registrar using this URL (https://evault.kfintech.com/ipostatus/).
Select company from dropdown menu.
Enter details- PAN, Application number or DP client ID
Get your allotment status
Open link to the registrar using this URL (https://evault.kfintech.com/ipostatus/).
IPO reads
Stay updated with the latest IPO developments
February 27, 2025 | 5 min read
₹50.11 Cr Balaji Phosphates IPO Opens Feb 28. Issue Details and SWOT AnalysisRead More
February 25, 2025 | 5 min read
Tata Capital Board Approves ₹15,000 Cr Plus Mega IPO; Tata Investment Shares Soar 8%Read More
February 18, 2025 | 5 min read
Busy Week Ahead: 2 SME IPOs and 9 Market Listings – Get the Complete Details HereRead More
October 25, 2024 | 5 min read
Waaree Energies IPO: GMP Soars 106% Amid 76.34x Subscription – Check Your Allotment Status!Read More
October 22, 2024 | 5 min read
Upcoming IPOs: 9 Public Issues Set to Raise ₹10,984.8 Cr – Key Insights Inside!Read More
October 17, 2024 | 5 min read
Hyundai IPO Hits a Speed Bump With 42% Subscription On Day 2 : 4 Reasons WhyRead More
September 6, 2024 | 5 min read
Bajaj Housing Finance IPO: All You Need to KnowRead MoreOctober 17, 2024 | 5 min read
Hyundai IPO Hits a Speed Bump With 42% Subscription On Day 2 : 4 Reasons WhyRead More
August 26, 2024 | 5 min read
Premier Energies IPO: Key Details Ahead of the ₹2,830.40 Cr Issue LaunchRead MoreMore on IPOs
Navigate your way to other IPO resources
Latest videos on IPOs
IPO highlights & details!
FAQs on IPO
Get answers to all your questions here!
The IPO opens on 24 Aug 2026 & closes on 27 Aug 2026.
Symbiotec Pharmalab Private Limited was incorporated as a private limited company, dated September 20, 2002, with the Registrar of Companies, Madhya Pradesh and Chhattisgarh. Subsequently, the name of the Company was changed to Symbiotec Pharmalab Limited and a fresh certificate of incorporation dated September 26, 2025, was issued by the Central Processing Centre.
Symbiotec is one of the few companies globally and only Indian manufacturer having continuous manufacturing for progesterone API manufacturing. The Company has its flow chemistry capability being utilized for progesterone in a new block in Pithampur facility. It is presently engaged in manufacturing and selling of Active Pharmaceuticals Ingredients (API) and Intermediates.
The Company has a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients. With over 30 years of industry experience, it has evolved from a lab-scale steroidal-hormone API manufacturer in year 1995 into an industrial-scale, backward-integrated platform with approvals from the United States Food and Drug Administration (USFDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea and other global organisations.
The Company started production of APIs at the Rau Facility in year 2004 and later commenced the same including hormone synthesis at the Pithampur Facility in 2010. In 2012, it commissioned a 5 KL biotech plant at Pithampur and a 35 kilolitres (KL) fermentation project at the Pithampur Facility.
The Company had two operational industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tons and fermentation capacity of 300 kilolitres. It has commissioned two additional manufacturing facilities, leading to an aggregate maximum chemical synthesis capacity of 584.67 MT, maximum fermentation capacity of 700 KL, and complex injectables capacity of 20 million vials per annum.
The Company later expanded a sterile plant at the Rau Facility in 2022-23. It has commissioned a complex injectables facility at the Mhow and further installed a 400 KL at the Ujjain Plant in FY 2025.
Company has filed a Draft Red Herring Prospectus with SEBI and is planning to raise funds through IPO aggregating to Rs 2180 crores, consisting a fresh offer of Rs 150 crore and the offer for sale of Rs 2030 crores having the face value of Rs 2 each.
Symbiotec Pharmalab Ltd IPO will close on 27 Aug 2026.
- Global leadership in corticosteroid and steroidal hormone APIs.
- Long-standing relationships with domestic and global customer base.
- Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record.
- Continuous investment in R&D, with leading technological capabilities among Indian peers.
- Ability to leverage science and existing competencies to increase total addressable market and deepen intellectual property-driven offerings.
| S.No | Promoters Name | Pre Issue Shares | Pre Issue Percentage | Post Issue Shares | Post Issue Percentage |
|---|---|---|---|---|---|
| 1 | Anil Satwani | 2810896 | 4.48 | 2810896 | 4.37 |
| 2 | Kashish Satwani | 2750896 | 4.38 | 2750896 | 4.28 |
| 3 | Sushil Satwani | 1233938 | 1.97 | 1233938 | 1.92 |
| 4 | Satwani Holdings LLP | 11277374 | 17.97 | 9819885 | 15.28 |
| 5 | Kashish and Anil Satwani Fami | 350000 | 0.56 | 350000 | 0.54 |
| 6 | Arjun Anil Satwani Family Tru | 2199104 | 3.5 | 2199104 | 3.42 |
| 7 | Krishna Anil Satwani Family T | 2199104 | 3.5 | 2199104 | 3.42 |
| 8 | Sunil Satwani | 10000 | 0.02 | 10000 | 0.02 |
| 9 | Swati Sachdev | 10000 | 0.02 | 10000 | 0.02 |
- The company derives almost all of its revenue from the sale of APIs, which collectively constituted 96.07%, 99.10% and 100.00% of the company's revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Further, its top five APIs constituted 62.27%, 63.16% and 60.37% of the company's revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Any reduction in demand for APIs, and its top products in particular, or disruption in production, could have an adverse effect on the company's business, results of operations, financial condition and cash flows.
- The company's manufacturing facilities is subject to periodic inspections and audits by regulatory authorities and its customers. Any manufacturing or quality control failures may subject it to regulatory action, damage the company's reputation and have an adverse effect on its business, results of operations, financial condition and cash flows.
- The company exports its products to various countries and the company's revenue from external customers outside India as per Ind AS 108 - "Operating Segments" represented 67.04%, 55.19% and 59.97% of its revenue from operations in Fiscals 2026, 2025 and 2024, respectively. The company's inability to handle risks associated with its export sales could adversely affect the company's sales to customers in foreign countries, its results of operations, financial condition and cash flows.
- In Fiscals 2026, 2025 and 2024, revenue from the United States represented 13.12%, 4.02% and 8.97% of the company's revenue from operations. The imposition of tariffs or other anti-outsourcing legislation by the United States could adversely affect its results of operations, financial condition and cash flows.
- The company derives a substantial portion of its revenue from certain key customers. Revenue generated from the company's top ten customers accounted for 57.59%, 55.90% and 61.65% of its revenue from sale of product in Fiscals 2026, 2025 and 2024, respectively. Loss of the company's relationship with any of these customers or delays or reductions in their orders could have an adverse effect on its business, results of operations, financial condition and cash flows.
- The company's manufacturing facilities and dedicated R&D centres are located in the state of Madhya Pradesh in India. Any adverse developments affecting Madhya Pradesh or its surrounding regions could adversely affect its business, results of operations, financial condition and cash flows. A slowdown, interruption or shutdown in the company's manufacturing operations could have an adverse effect on its business, results of operations, financial condition and cash flows.
- The company depends on certain suppliers for raw materials for its operations. Purchases from the company's top ten suppliers accounted for 25.50%, 18.41% and 50.33% of its total expenses in Fiscals 2026, 2025 and 2024, respectively. Any loss of such suppliers or non-performance of their obligations could adversely affect the company's business, results of operations, financial condition and cash flows.
- The company operates in a highly competitive market. Its faces competition both within the company's API manufacturing business and in its role as a CDMO, which the company has recently commenced. An inability to compete effectively may adversely affect its business, results of operations, financial condition and cash flows.
- The company procures a portion of its raw material requirements from different countries, including China and the United States. Any adverse developments in these countries, or the laws governing the company's imports from these countries, could disrupt its raw material supply and adversely affect the company's results of operations, financial condition and cash flows.
- The company's success depends on its ability to develop and commercialise new products in a timely manner. If the company's research and development efforts does not succeed, or the products its commercialise does not perform as expected, the introduction of new products may be hindered, which could adversely affect the company's business, results of operations, financial condition and cash flows.
- The company's operations involve activities and materials which is hazardous in nature and could result in a suspension of operations, injury to its personnel, emission of pollutants or the imposition of civil or criminal liabilities, which could adversely affect the company's business, results of operations, financial condition and cash flows.
- The company is subject to extensive regulation from governmental and international authorities and if the company fails to obtain, maintain or renew the statutory and regulatory licenses, permits and approvals required for its business, the company's results of operations, financial condition and cash flows may be adversely affected. Further, non-compliance with, and changes in, environmental, health and safety, and labor laws and other applicable regulations may adversely affect its business, results of operations, financial condition and cash flows.
- The company has issued Equity Shares during the preceding 12 months at prices that may be lower than the Offer Price.
- The company's business agreements include certain restrictive covenants which may restrict its business operations.
- If the company's products or other products containing its corticosteroid or steroidal-hormone APIs cause, or are perceived to cause, severe side effects, the sales of such products may decrease, which may have an adverse effect on the company's results of operations, financial condition and cash flows.
- The company's operations are labour intensive, and its may be subject to strikes, work stoppages or increased wages demands by the company's employees, which could adversely affect its business, results of operations, financial condition and cash flows.
- The company requires working capital for its continued operation and growth. The company's inability to meet its working capital requirements could have an adverse effect on the company's business, results of operations, financial condition and cash flows.
- The company's statutory auditors examination report on the Restated Consolidated Summary Statements discloses certain modifications included in their report on the consolidated financial statements as at and for the years ended March 31, 2026, March 31, 2025 and March 31, 2024.
- The company has in the past been in non-compliance with Section 383A of the Companies Act, 1956 and have filed a compounding application with the National Company Law Tribunal, Indore ("NCLT, Indore"). Its cannot assure you that there will be no such non-compliances in the future and that the company will not be subject to any action including payment of penalty amount.
- Motilal Oswal Investment Advisors Limited, one of the Book Running Lead Managers, is an associate of one of the company's Investor Selling Shareholders, namely, India Business Excellence Fund - III.
- The company's past performance may not be indicative of its future growth. The company may not be able to effectively sustain its growth or execute the company's growth strategies, which could have an adverse effect on its business, results of operations, financial condition and cash flows.
- The company may not be successful in commercialising its complex injectables offerings, which the company intends to focus on through the commissioned Mhow Facility, which may adversely affect the company's results of operations, financial condition and cash flows.
- Certain of the company's raw materials and production processes are sensitive and must be collected, stored and transported in specific conditions. Failures to handle these materials and products appropriately, or undertake the sensitive processes with their complex steps, may lead to loss of the raw materials, inability to sell the products and adversely affect the company's business, results of operations, financial condition and cash flows.
- Some of the company's Promoters and Directors may have interest in entities in businesses similar to its, which may result in conflicts of interest with it.
- The company is in the process of expanding its biologics capacity by setting up the Biologics Facility in Ujjain. The establishment of this facility may be subject to delays, cost overruns, or other risks and uncertainties.
- The company's CDMO business, which commenced in 2025 and which the company is expanding, is subject to risks including seasonality, which may result in seasonal fluctuations in operating results and cash flows, non-compliance with the terms of its contracts with customers, and expiry of patent protection of customers and limited number of customers. Any failures to grow the company's CDMO business or mitigate these risks could adversely affect its results of operations, financial condition and cash flows.
- The company's benefit from incentives and schemes of the Government of India. Cancellation of such incentives and schemes, or its inability to meet their conditions, may adversely affect the company's results of operations, financial condition and cash flows.
- Introduction of stricter norms regulating pharmaceutical marketing practices could affect the company's ability to effectively market its products, which may have an adverse effect on the company's business, results of operations and financial condition.
- The company has entered into certain transactions with related parties in the past and may continue to do so in the future. These transactions or any future transactions with its related parties could potentially involve conflicts of interest.
- The company's operations are dependent on an adequate and uninterrupted external supply of electricity, fuel, and water. Any disruption or shortage in electricity, fuel or water may lead to disruption in operations, higher operating cost and consequent decline in the company's operating margins.
- The Investor Selling Shareholders, India Business Excellence Fund-III, together with its co-investors, and Rosewood Investments, have transferred Equity Shares held by them, to one of the company's Promoters, Satwani Holdings LLP, pursuant to the upside sharing arrangement as provided for in the Investment Agreement which has resulted in an increase in the pre-Offer shareholding of its Promoter, Satwani Holdings LLP.
- There are certain restrictions on operations within a special economic zone ("SEZ") in India. The company's claim deductions under special tax holidays for its Pithampur Facility, located in an SEZ in India. Any change in these tax holidays, or failures to comply with restrictions applicable to SEZs, may adversely affect its results of operations, financial condition and cash flows.
- Delay or failures in the performance of the company's contracts may adversely affect its business, results of operations, financial condition and cash flows.
- If the company is unable to protect its proprietary information or other intellectual property, the company's business may be adversely affected.
- Certain of the company's manufacturing facilities are not located on land owned by it and the company has only leasehold rights. In the event its loses or is unable to renew such leasehold rights, the company's business, results of operations, financial condition and cash flows may be adversely affected.
- Certain of the company's corporate records and filings are not traceable or have certain discrepancies. Its cannot assure you that regulatory proceedings or actions will not be initiated against the company in the future and its will not be subject to any penalty imposed by the competent regulatory authority in this regard.
- Under-utilisation of the company's manufacturing capacities over extended periods, or significant underutilisation in the short term could increase its cost of production and the company's operating costs and adversely impact its business, growth prospects and future financial performance.
- The company's Promoters and certain members of the Promoter Group have encumbered certain Equity Shares of the Company held by them in favour of Beacon Trusteeship Limited, (on behalf of debenture holder, Nomura Capital (India) Private Limited, which is an affiliate of one of its BRLMs, Nomura Financial Advisory and Securities (India) Private Limited) by way of pledge. Any enforcement of such pledge by Beacon Trusteeship Limited could dilute the shareholding of the company's Promoters, which may adversely affect its business and financial condition.
- The company held a market share of over 50% by volume in products such as Hydrocortisone, Testosterone and Methylprednisolone, with market shares of 80.1%, 76.4% and 76.0% respectively, in Fiscal 2026. (Source: F&S Report) The loss of market share may adversely affect its business, results of operations, financial condition and cash flows.
- The company has capital expenditure requirements and may requires additional capital and financing in the future. If the company is unable to obtain the required additional capital and financing when needed, its results of operations, financial condition and cash flows may be adversely affected.
- The company proposes to repay or prepay all or a portion of certain outstanding borrowings availed by the Company.
- The company's Promoter and Chairman and Managing Director, Anil Satwani, has provided personal guarantees for certain borrowings availed by one of its Subsidiaries. Any failures by the Company to repay such loans could trigger repayment obligations on the company's Promoter, which may impact their ability to effectively service their obligations and adversely affect its business and operations.
- The company has extended certain loans to its Subsidiaries, and extended guarantees on their behalf. Any default by the Subsidiaries in fulfilling their obligations in connection with such indebtedness may lead to nonrecovery or invocation of the guarantees, which could adversely affect the company's results of operations, financial condition and cash flows.
- The company is exposed to risks in relation to the supply of its products, particularly through third party transportation. A failures to deliver the company's products to its customers in an efficient and reliable manner could have an adverse effect on the company's business, results of operations, financial condition and cash flows.
- The Company and certain of its Directors and Subsidiaries are involved in certain legal proceedings. Any adverse decision in such proceedings may have an adverse effect on the company's business, results of operations, financial condition and cash flows.
- The company's funding requirements and proposed deployment of the Net Proceeds of the Offer have not been appraised by a bank or a financial institution and if there are any delays or unanticipated expenses, its business, cash flows, financial condition and results of operations may be adversely affected.
- The company's continued success is dependent on its Promoters, Directors, Senior Management, Key Managerial Personnel and skilled manpower. The company's inability to attract and retain key personnel or the loss of services of such personnel may have an adverse effect on its business prospects.
- The Company will not receive any proceeds from the Offer for Sale.
- The company may pursue strategic acquisitions for inorganic growth in the future. Its may not be able to integrate any future acquisitions or may be faced with operating difficulties due to such integration, which could adversely affect the company's business, results of operations, financial condition and cash flows.
- Changes in technology may render the company's current technologies obsolete or requires it to make substantial capital investments.
- The company is subject to risks arising from exchange rate fluctuations. Failures to effectively manage such risks could adversely affect its results of operations, financial condition and cash flows.
- The company engage contract labour for carrying out certain functions of its business operations. Any default on payments to them by the agencies could lead to disruption of the company's business operations.
- Information technology system failures or interruptions or breaches of the company's network security, confidentiality of technical knowledge and process know-how may interrupt its operations adversely impact the company's business, results of operations, financial condition, cash flows, reputation and prospects.
- The company may be subject to pricing pressure from its customers, which could have an adverse effect on the company's business, results of operations, financial condition and cash flows.
- Certain sections of this Red Herring Prospectus disclose information from the F&S Report which has been prepared exclusively for the Offer and commissioned and paid for by it exclusively in connection with the Offer and any reliance on such information for making an investment decision in the Offer is subject to inherent risks.
- The company's insurance coverage may not adequately protect it against all losses or the insurance cover may not be available for all the losses as per the insurance policy, which could adversely affect business, results of operations, financial condition and cash flows.
- Certain of the company's Subsidiaries have incurred losses during the last three Fiscals and certain of its Subsidiaries have reported negative net worth in the last three Fiscals. The company cannot assure you that its Subsidiaries will be able to generate profits and not incur losses in the future or not report negative net worth.
- Any inability to recover amounts deployed in the company's Subsidiaries, including overseas Subsidiaries, resulting in write-offs may adversely affect its business, results of operations, financial condition and cash flows.
- Information relating to the maximum manufacturing capacity and capacity utilisation of the company's facilities included in this Red Herring Prospectus are based on various assumptions and estimates. These assumptions and estimates may prove to be inaccurate, and its future production and capacity may vary.
- The company's inability to accurately forecast demand for its products and manage the company's inventory may have an adverse effect on its business, results of operations, financial condition and cash flows.
- Any negative publicity or allegations against it, even if untrue, may adversely affect its reputation and trust in the company's services, which could adversely affect its business, results of operations, financial condition and cash flows.
- The company has incurred indebtedness and an inability to comply with repayment and other covenants in the company's financing agreements could adversely affect its business, results of operations, financial condition and cash flows.
- Failures in internal control systems could cause operational errors which may have an adverse effect on the company's reputation, results of operations, financial condition and cash flows.
- The company is subject to counterparty credit risk and any delay in receiving payments, or non-receipt of payments, from its customers could have an adverse effect on the company's business, results of operations, financial condition and cash flows.
- If the company inadvertently infringe on the intellectual property rights of others, its business, results of operations, financial condition and cash flows may be adversely affected.
- The company's operations are susceptible to the risk of manufacture, distribution, and sale of counterfeit, falsified, or sub-standard drugs, particularly in the generic drug segment. Any failures to prevent or detect counterfeit products associated with its brand may have an adverse impact on the company's business, results of operations, financial condition and cash flows.
- Any downgrade of the company's credit ratings could adversely affect its business.
- The company's Promoters, including its Chairman and Managing Director, and certain members of the company's Key Managerial Personnel and Senior Management, hold Equity Shares in the Company and are therefore interested in the Company's performance in addition to their remuneration and reimbursement of expenses.
- The company's Promoters and members of the Promoter Group will continue to hold a significant equity stake in the Company after the Offer and their interests may differ from those of the other shareholders.
- Certain non-GAAP financial measures relating to the company's operations and financial performance have been included in this Red Herring Prospectus. These non-GAAP financial measures are not measures of operating performance or liquidity defined by Ind AS and may not be comparable.
- Any variation in the utilisation of the Net Proceeds as disclosed in this Red Herring Prospectus shall be subject to certain compliance requirements, including prior approval of the shareholders of the Company.
- The company's ability to pay dividends in the future will depends upon its future earnings, financial condition, cash flows, working capital requirements and capital expenditures and the terms of the company's financing arrangements.
- Theft, internal or external fraud or misconduct by the company's employees could adversely affect its results of operations, financial condition and cash flows.
- The company has adopted the Symbiotec Employee Stock Option Plan 2024 ("ESOP Scheme"). The grant of options under the ESOP Scheme may increase the company's employee expenses and may adversely impact its profitability and cash flows.
- The markets addressed by the company subject to certain threats and challenges, which could adversely affect its business, results of operations, financial condition and cash flows.
- If the company's products are found to be infringing on the intellectual property rights of a third-party, its may be required to cease the sale of such infringing products, causing loss of future sales revenue from such products and may also faces liabilities for infringement of intellectual property rights, which may adversely affect the company's business, results of operations, cash flows and financial condition.
The Issue type of Symbiotec Pharmalab Ltd is Book Building.
The minimum application for shares of Symbiotec Pharmalab Ltd is 15.
The total shares issue of Symbiotec Pharmalab Ltd is 17786442.
Initial public offering of 17,786,442 equity shares of face value of Rs. 2 each ("Equity Shares") of the company for cash at a price of Rs. 988.00 per equity share ( Including a Share Premium of Rs. 986.00 Per Equity Share) ("Offer Price") aggregating Rs. 1757.00 Crores ("Offer"). The offer comprised a fresh issue of 1,521,261 equity shares of face value of Rs. 2 each aggregating Rs. 150.00 Crores by the company ("Fresh Issue") and an offer for sale of 16,265,181 equity shares of face value of Rs. 2 each ("Offered Shares") aggregating Rs.1607.00 Crores, comprising of 1,457,489 equity shares of face value of Rs. 2 each aggregating Rs. 144.00 Crores by Satwani Holdings LLP (the "Promoter Selling Shareholder"), 10,000,000 equity shares of face value of Rs. 2 each aggregating Rs.988.00 Crores by Rosewood Investments and 4,807,692 equity shares of face value of Rs. 2 each aggregating Rs. 475.00 Crores by India Business Excellence fund - III (the "Investor Selling Shareholders", and together with the promoter selling shareholder, the "Selling Shareholders" and such offer for sale of equity shares by the selling shareholders, the "Offer For Sale"). The offer will constituted 27.68% of the post-offer paid up equity share capital of the company.
The offer includes a reservation of 33,407 equity shares of face value of Rs. 2 each aggregating Rs. 3.00 Crores ( Constituting 5% of the post offer paid-up equity share capital of the company), for subscription by eligible employees (the "Employee Reservation Portion"). The offer less the employee reservation portion is hereinafter referred to as the "Net Offer". The offer and the net offer shall constitute 27.68% and 27.63%, respectively, of the post-offer paid-up equity share capital of the company. The company, in consultation with the book running lead managers, may offer a discount of 9.11% (equivalent to Rs.90.00 per equity share) to the offer price to eligible employees bidding under the employee reservation portion ("Employee Discount").
Price Band: Rs. 988 per equity share of face value of Rs. 2 each.
The floor price is 494.00 times of the face value of the equity shares.
Bids can be made for a minimum of 15 equity shares of face value of Rs. 2 each and in multiples of 15 equity shares of face value of Rs. 2 each thereafter.
Discount of Rs. 90.00 per equity share of face value of Rs. 2 is being offered to eligible employees bidding in the employee reservation portion.